Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: Biojunkie who wrote (32)	3/19/1998 5:26:00 PM
From: Bill Wexler	Respond to of 138

Ladies and gentlemen...the first HEPH stock tout has arrived!!!

To: Biojunkie who wrote (32)	3/19/1998 7:22:00 PM
From: BDR	Read Replies (1) \| Respond to of 138

<<Thanks for providing us with your insight and understanding of bioavailability (how much drug gets into the bloodstream)with regards to the hormone which you've mentioned is available at your corner drug/healthfood store. >> I did? All I offered were quotes from the company's own material. I don't recall providing bioavailability data. <<Wouldn't it be a shame if you shorted a company that may have a less expensive, easier to use drug that dramatically inhibits HIV replication?>> It would be, but do you have references to support that claim for the drug? (Jumper- we won't need your services. A real long has surfaced.)

To: Biojunkie who wrote (32)	3/20/1998 8:31:00 AM
From: Bradpalm1	Read Replies (1) \| Respond to of 138

Biojunkie, I find proposed pharmacological mechanisms of Inactivin and Reversionex very unusual. Do you have any more information or references regarding these two novel drugs? Bradpalm1